Commonwealth Equity Services LLC Has $1.78 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Posted by on May 18th, 2023

Commonwealth Equity Services LLC lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) by 7.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 154,699 shares of the biotechnology company’s stock after selling 12,831 shares during the period. Commonwealth Equity Services LLC owned approximately 0.08% of BioCryst Pharmaceuticals worth $1,775,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Huntington National Bank raised its position in BioCryst Pharmaceuticals by 24.0% in the third quarter. Huntington National Bank now owns 5,582 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 1,081 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of BioCryst Pharmaceuticals by 5.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,667 shares of the biotechnology company’s stock worth $306,000 after buying an additional 1,345 shares in the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of BioCryst Pharmaceuticals by 3.0% during the third quarter. Ensign Peak Advisors Inc now owns 53,360 shares of the biotechnology company’s stock worth $672,000 after buying an additional 1,530 shares in the last quarter. Fairfield Bush & CO. acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $34,000. Finally, LPL Financial LLC increased its holdings in shares of BioCryst Pharmaceuticals by 10.1% during the fourth quarter. LPL Financial LLC now owns 24,305 shares of the biotechnology company’s stock worth $279,000 after buying an additional 2,228 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on BCRX shares. StockNews.com lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Thursday, April 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, March 14th. JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 22nd. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $15.00.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $8.47 on Thursday. BioCryst Pharmaceuticals, Inc. has a one year low of $7.20 and a one year high of $15.43. The company’s 50 day simple moving average is $8.19 and its 200-day simple moving average is $10.01. The stock has a market capitalization of $1.60 billion, a P/E ratio of -7.00 and a beta of 2.01.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last announced its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The business had revenue of $68.80 million during the quarter, compared to the consensus estimate of $71.44 million. During the same period in the previous year, the business posted ($0.40) earnings per share. BioCryst Pharmaceuticals’s revenue was up 37.9% compared to the same quarter last year. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -1.03 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

(Get Rating)

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.

Read More

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.